<DOC>
	<DOCNO>NCT03030235</DOCNO>
	<brief_summary>The primary purpose study evaluate impact dapagliflozin , compare placebo , heart failure , disease specific biomarkers , symptom , health status quality life patient type 2 diabetes prediabetes chronic heart failure preserve systolic function .</brief_summary>
	<brief_title>Dapagliflozin Type 2 Diabetes Pre-diabetes , PRESERVED Ejection Fraction Heart Failure</brief_title>
	<detailed_description>A 12-week randomized , double-blind , placebo-controlled trial evaluate effect once-daily dapagliflozin 10 mg heart failure disease-specific biomarkers ( NTproBNP BNP ) , symptom , health status , quality life patient type 2 diabetes prediabetes chronic heart failure preserve systolic function . An imaging substudy also conduct explore effect dapagliflozin vs. placebo various echocardiographic parameter .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Prediabetic State</mesh_term>
	<mesh_term>Glucose Intolerance</mesh_term>
	<criteria>1 . Documented type 2 diabetes least 3 month , prediabetes . Those type 2 diabetes must prescribe lifestyle intervention alone combination stable dose ( ) least one glucoselowering medication 8 week prior screen visit . 2 . Hemoglobin A1c inclusion criterion follow : i. Hemoglobin A1c 611 % ( inclusive ) patient document type 2 diabetes receive metformin monotherapy ; ii . Hemoglobin A1c 6.511 % ( inclusive ) patient document type 2 diabetes receive type glucoselowering medication ( except metformin monotherapy ) ; iii . Hemoglobin A1c 6.06.9 % ( inclusive ) patient document type 2 diabetes receive lifestyle intervention alone ; iv . Hemoglobin A1c &gt; 5.7 % &lt; 6.5 % patient prediabetes 3 . Symptoms dyspnea ( NYHA class IIIV ) without evidence noncardiac ischemic explanation dyspnea 4 . Ejection fraction ( EF ) ≥ 45 % determine image study within 18 month enrollment change clinical status suggest potential deterioration systolic function 5 . Elevated NTproBNP ≥ 300 pg/ml BNP ≥ 100 pg/ml . For patient permanent atrial fibrillation inclusion threshold BNP ≥ 125 pg/mL NTproBNP ≥ 500 pg/mL 6 . Stable medical therapy heart failure 30 day 7 . On diuretic ≥30 day prior screen visit stable diuretic therapy 14 day 8 . At least one following : . Hospitalization decompensated HF last 12 month ; ii . Acute treatment HF intravenous loop diuretic hemofiltration last 12 month ; iii . Mean pulmonary capillary wedge pressure ≥15 mmHg LV end diastolic pressure ( LVEDP ) ≥15 mmHg document catheterization rest , pulmonary capillary wedge pressure LVEDP ≥25 mmHg document catheterization exercise ; iv . Structural heart disease evidence least one follow echo finding ( local measurement make within 18 month prior screen visit ) : 1 ) leave atrial ( LA ) enlargement define least one following : LA width ≥3.8cm LA length ≥5.0 cm LA area ≥20 cm2 LA volume ≥55mL LA volume index ≥29 mL/m2 2 ) OR leave ventricular hypertrophy ( LVH ) define septal thickness posterior wall thickness ≥1.1 cm . 1 . Decompensated heart failure ( hospitalization heart failure within 30 day prior screen ) 2 . History type 1 diabetes 3 . History diabetic ketoacidosis 4 . Hemoglobin A1c &lt; 5.7 &gt; 11 % screen visit 5 . Estimated glomerular filtration rate ( eGFR ) &lt; 30 screen visit 6 . Admission acute coronary syndrome ( STelevation MI , nonSTelevation MI , unstable angina ) , percutaneous coronary intervention , cardiac surgery within 60 day prior screen visit . 7 . Admission cardiac resynchronization therapy ( CRT ) within 90 day prior screen visit 8 . Planned cardiovascular revascularization ( percutaneous intervention surgical ) major cardiac surgery ( coronary artery bypass grafting , valve replacement , ventricular assist device , cardiac transplantation , surgery require thoracotomy , transcatheter aortic valve replacement ) CRT within 90 day screen visit . 9 . Participation interventional clinical trial ( investigational drug device ) observational registry within 30 day screen visit . 10 . History hypersensitivity dapagliflozin 11 . For woman childbearing potential : Current planned pregnancy currently lactate . 12 . Life expectancy &lt; 1 year screen visit 13 . Patients volume deplete base upon physical examination time screen randomization visit 14 . BNP &lt; 100 pg/mL NTproBNP &lt; 300 pg/mL screen visit . For patient permanent atrial fibrillation exclusion threshold BNP &lt; 125 pg/mL NTproBNP &lt; 500pg/mL . 15 . Patients currently treat SGLT2 inhibitor ( dapagliflozin , canagliflozin , empagliflozin ) receive treatment SGLT2 inhibitor within 12 week prior screen visit . 16 . Average supine systolic BP &lt; 100 mmHg screen randomization visit 17 . Past current history bladder cancer 18 . Active Hematuria 19 . Donation blood bone marrow 12 week prior screen visit plan donation study period 20 . Heart failure due restrictive/infiltrative cardiomyopathy , active myocarditis , constrictive pericarditis , severe stenotic valve disease , HOCM ( hypertrophic obstructive cardiomyopathy ) . 21 . Heart failure due severe aortic mitral regurgitation 22 . Severe COPD think contribute dyspnea 23 . Isolated right heart failure due pulmonary disease 24 . Active significant ischemia think contribute dyspnea 25 . Documentation previous EF &lt; 40 % time 26 . Complex congenital heart disease 27 . Uncontrolled hypertension , define systolic blood pressure ≥200 mmHg screen visit 28 . Any condition judgment investigator would jeopardize patient 's participation study may interfere interpretation study data patient consider unlikely comply study procedure , restriction requirement 29 . Bariatric surgery within past 6 month plan bariatric surgery within study time course . 30 . CardioMems device implantation within previous 4 week plan CardioMems implantation study period 31 . For echo substudy : history poor echo window judge investigator 32 . For echo substudy : patient ventricular pace rhythm leave bundle branch block recent clinically available 12lead electrocardiogram . 33 . For echo substudy : permanent atrial fibrillation</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>119 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>heart failure</keyword>
	<keyword>dapagliflozin</keyword>
	<keyword>SGLT-2 inhibitor</keyword>
</DOC>